IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders. |
On December 20, 2016, Immune Pharmaceuticals Inc. (the Company)
held its 2016 Annual Meeting of Stockholders (the Annual
Meeting). At the Annual Meeting, the holders of 78,497,800 shares
of the voting stock of the Company were present in person or
represented by proxy, which represents approximately 63% of the
total shares of outstanding stock entitled to vote as of the
record date of October 21, 2016.
The following actions were taken in the Annual Meeting:
| (1) |
The selection of BDO USA, LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote | |||||||||||
| 74,558,639 | 2,232,794 | 1,706,367 | ||||||||||||
| (2) |
The increase in the amount of shares authorized under the Immune Pharmaceuticals Inc. 2015 Equity Incentive Plan from 5,000,000 shares to 15,000,000 shares was approved, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote | |||||||||||
| 38,243,946 | 9,238,861 | 2,292,644 | 28,722,349 | |||||||||||
| (3) |
The following two Class III nominees were reelected to serve on the Companys Board of Directors until the Companys 2019 annual meeting of stockholders or until their respective successors have been elected and qualified: |
| Name of Director Nominees | Votes For | Votes Abstain | Broker Non-Vote | |||||||||
| Daniel G. Teper | 48,597,134 | 1,178,317 | 28,722,349 | |||||||||
| John Neczesny | 35,953,441 | 13,822,010 | 28,722,349 | |||||||||
| (4) |
The authorization of the filing of an amendment to the Companys Certificate of Incorporation to effect a reverse stock split of the Companys common stock at a specific ratio, within a range of 1-for-2 and 1-for-25, to be determined by the Companys Board of Directors in its sole discretion and effected, if at all, on or before December 15, 2017 was approved, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote | |||||||||||
| 62,751,519 | 13,102,528 | 2,643,750 | ||||||||||||
|
– – |
About IMMUNE PHARMACEUTICALS INC. (NASDAQ:IMNP)
